Pharmacoeconomic review report: Fluticasone propionate (Aermony Respiclick) (Teva Canada Innovation) indication : for the maintenance treatment of steroid-responsive bronchial asthma as prophylactic therapy in patients 12 years of age and older
Fluticasone propionate (Fp) is an inhaled corticosteroid (ICS), available as a multidose dry powder inhaler (MDPI) (Fp MDPI; Aermony RespiClick). It is indicated for the maintenance treatment of steroid-responsive bronchial asthma in patients 12 years of age or older. The submitted price for a 60-do...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
January 2019, 2019
|
| Edition: | Final (with redactions) |
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Fluticasone propionate (Fp) is an inhaled corticosteroid (ICS), available as a multidose dry powder inhaler (MDPI) (Fp MDPI; Aermony RespiClick). It is indicated for the maintenance treatment of steroid-responsive bronchial asthma in patients 12 years of age or older. The submitted price for a 60-dose pack of Fp MDPI is $16.96 for 55 mcg, $30.96 for 113 mcg, and $48.15 for 232 mcg. The dose of Fp MDPI depends on the severity of the disease. At the recommended dose, administration of one inhalation twice daily, Fp MDPI costs between $206 and $586 per patient per year. Fp is available as an individual treatment in several different inhaler formats, including Fp Diskus (Flovent Diskus) and Fp hydrofluoroalkane (HFA) (Flovent HFA), though none of these were reviewed by CDEC. |
|---|---|
| Physical Description: | 1 PDF file (14 pages) |